SciSparc

growth-positive

N2OFF Inc., a cleantech company, has completed a merger with MitoCareX Bio Ltd., a biotech firm specializing in cancer therapeutics. The merger, finalized on October 20, 2025, involved N2OFF acquiring MitoCareX, making it a wholly-owned subsidiary. The acquisition was executed through a combination of cash and stock, with N2OFF purchasing shares from SciSparc Ltd and other sellers. The agreement includes financial commitments from N2OFF to support MitoCareXs operations for two years. This merger is expected to enhance N2OFFs portfolio by integrating MitoCareXs innovative cancer treatment technologies, potentially boosting growth in the biotech sector.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has completed a significant transaction under an asset and share purchase agreement with Miza III Ventures Inc. and SciSparc Nutraceuticals Inc. As a result, SciSparc acquired a controlling interest in Neurothera Labs Inc., a publicly traded company on the TSX Venture Exchange. The transaction involved SciSparc transferring its advanced clinical stage pharmaceutical portfolio and a 51% equity stake in SciSparc Nutraceuticals Inc. to Neurothera. The total enterprise value of Neurothera was approximately US$3.3 million, while the Target Assets were valued at approximately US$11.6 million. Following the transaction, SciSparc holds a 75% controlling interest in Neurothera, which could increase to 84% upon meeting certain milestones.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a new initiative to advance 3D protein modeling using quantum computing technology. This initiative aims to transform drug discovery by achieving unprecedented accuracy in predicting protein structures and interactions, potentially leading to breakthroughs in structural biology and personalized medicine. SciSparc plans to form a dedicated research team and collaborate with experts in quantum computing and structural biology. The company will focus on refining quantum algorithms for applications in drug discovery, particularly for neurological and rare diseases. SciSparc also plans to incorporate a new wholly owned Israeli subsidiary to operate this initiative.

growth-negative

SciSparc Ltd, a clinical-stage pharmaceutical company, announced the sale of its majority-owned subsidiary, MitoCareX Bio Ltd, to N2OFF, Inc. MitoCareX focuses on developing therapies for hard-to-treat cancers using its proprietary algorithm, MITOLINE™, for identifying anti-cancer small molecule therapeutics. The transaction, which closed on October 20, 2025, involved N2OFF purchasing shares of MitoCareX for $700,000 and exchanging remaining shares for N2OFFs common stock. As a result, MitoCareX became a wholly owned subsidiary of N2OFF. The sellers, including SciSparc, are entitled to milestone-based issuances of N2OFFs common stock and a share of N2OFFs financing proceeds for five years.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has entered into a definitive asset and share purchase agreement with Miza III Ventures Inc. As part of the agreement, SciSparc will transfer its advanced clinical-stage pharmaceutical portfolio and a 51% equity stake in SciSparc Nutraceuticals Inc. to Miza in exchange for a controlling interest in Miza. The transaction values SciSparcs assets at approximately $11.6 million. Following the transaction, SciSparc will hold between 75% and 84% of Miza, which will be renamed NeuroThera Labs Inc. The TSXV has conditionally approved the transaction, and SciSparc plans to commit up to CAD 1,000,000 in capital to Miza through a convertible note.

growth-negative

SciSparc Ltd. announced the termination of its planned merger with AutoMax Motors Ltd., ending a deal that would have expanded its operations into Israels automotive market. The companies agreed on repayment terms for prior loans, with AutoMax set to repay $4.25 million plus interest by 2028. The merger, initially agreed upon in April 2024, aimed to diversify SciSparcs operations into vehicle import and electric vehicle markets. Despite the cancellation, SciSparc will continue focusing on its central nervous system disorder treatments and advancing drug discovery using quantum algorithms. The companys shares saw a slight increase following the announcement.

growth-negative

SciSparc Ltd, a clinical-stage pharmaceutical company, announced the mutual termination of its merger agreement with AutoMax Motors Ltd. The termination resolves prior commitments and establishes repayment terms for SciSparcs outstanding loans to AutoMax. The agreement includes the repayment of a $4.25 million loan with interest by January 1, 2028, and a $2.0 million loan in monthly installments starting November 20, 2025. SciSparc focuses on developing therapies for central nervous system disorders using cannabinoid pharmaceuticals. The termination of the merger is seen as a growth-negative event for SciSparc, as it impacts their strategic plans.

growth-negative

SciSparc Ltd, a clinical-stage pharmaceutical company, announced that its majority-owned subsidiary, MitoCareX Bio Ltd, will be acquired by N2OFF, Inc. The acquisition was approved by N2OFFs stockholders on September 25, 2025. MitoCareX focuses on developing therapies for hard-to-treat cancers using advanced drug discovery techniques. Under the agreement, N2OFF will purchase shares of MitoCareX for $700,000 and exchange remaining shares for N2OFFs common stock, making MitoCareX a wholly owned subsidiary. The Sellers, including SciSparc, will receive a portion of N2OFFs financing proceeds and milestone-based stock issuances. This acquisition marks a significant change for SciSparc as it divests its interest in MitoCareX.

growth-positive

PepGen (PEPG) shares experienced an increase on Thursday following the companys announcement on Wednesday that it achieved a significant milestone. The article suggests a positive impact on the companys growth, as reflected in the rise of its stock value. However, the article is part of a premium news service, requiring a subscription to access the full content. No specific details about the nature of the achievement or other business activities such as partnerships, investments, or acquisitions are provided in the available text.

growth-positive

N2OFF Inc., a cleantech company focused on solar energy, announced the acquisition of MitoCareX Bio Ltd., a biotech firm specializing in cancer therapeutics. The acquisition was approved by N2OFFs stockholders on September 25, 2025. MitoCareX focuses on drug discovery targeting the mitochondrial SLC25 protein family to treat hard-to-treat cancers. N2OFF will acquire full ownership from SciSparc Ltd and other sellers for $700,000 and exchange shares, making MitoCareX a wholly owned subsidiary. The agreement includes a financial commitment to support MitoCareXs operations with an initial $1,000,000 investment. The transaction is expected to close by October 2025.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a new initiative to advance 3D protein modeling using quantum computing technology. This initiative aims to transform drug discovery by achieving unprecedented accuracy in predicting protein structures and interactions with ligands. The company plans to form a dedicated research team and collaborate with experts in quantum computing and structural biology. The focus will be on developing quantum-enabled tools to predict protein folding, model protein-ligand interactions, and accelerate drug discovery, particularly for neurological and rare diseases. SciSparc will incorporate a new wholly owned Israeli subsidiary to operate this initiative.

The article from MT Newswires, dated September 17, 2025, briefly mentions that US stocks are expected to open relatively unchanged in Wednesdays trading session. The article does not provide specific details about any particular company or event. It appears to be a general market update rather than focusing on a specific company or industry development.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced the approval of a strategic merger with AutoMax Motors Ltd, a leading vehicle importer in Israel. This merger, approved by both companies shareholders, will result in SciSparc acquiring 100% of AutoMax’s share capital through a reverse merger. This move is part of SciSparc’s strategy to diversify its portfolio and enter the electric vehicle market in Israel. SciSparc has supported AutoMax with financial assistance, including a $4.25 million bridge loan in 2024 and an additional $2 million loan in February 2025. The merger is expected to enhance SciSparc’s shareholder value by expanding its operations into the automotive sector.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced the approval of a strategic merger with AutoMax Motors Ltd, a leading vehicle importer in Israel. The merger, approved by SciSparcs shareholders, will result in SciSparc acquiring 100% of AutoMaxs share capital through a reverse merger. This move is part of SciSparcs strategy to diversify its portfolio and enter the electric vehicle market in Israel. SciSparc has supported AutoMaxs growth with financial assistance, including a $4.25 million bridge loan in 2024 and an additional $2 million loan in February 2025. The merger is expected to enhance shareholder value and expand SciSparcs operations into the automotive sector.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of an international patent application under the Patent Cooperation Treaty. This is part of its collaboration with SciSparc Ltd., focusing on developing novel psychedelic-derived therapeutics. The patent covers a combination therapy using Clearminds MEAI and SciSparcs PEA for treating metabolic syndrome and obesity. This marks a significant milestone in their collaboration, which has resulted in 13 patent families across multiple jurisdictions. The therapy aims to leverage MEAIs pharmacological profile and PEAs properties to offer a safe and effective treatment for metabolic conditions. Clearminds strategy is to develop breakthrough therapies for complex health conditions, potentially redefining therapeutic approaches for metabolic syndrome and obesity.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a significant milestone in its collaboration with Clearmind Medicine Inc. The partnership has resulted in the publication of an international patent application under the Patent Cooperation Treaty. This patent covers a novel combination therapy for treating metabolic syndrome and obesity, leveraging Clearminds MEAI and SciSparcs PEA. The collaboration aims to develop innovative therapies for mental health disorders and metabolic conditions. SciSparc focuses on cannabinoid pharmaceuticals and is engaged in drug development programs for conditions like Tourette Syndrome and Alzheimers disease. The company also has a subsidiary selling hemp seed oil products on Amazon.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced progress in its proposed merger with AutoMax Motors Ltd, an electric vehicle importer. The merger involves SciSparc acquiring 100% of AutoMaxs share capital via a reverse merger. The merger is subject to customary closing conditions, including shareholder and Israeli court approvals. Special meetings for shareholder votes are scheduled for August 2025. The SEC has declared effective the registration statement for the merger. SciSparc focuses on developing cannabinoid-based therapies for central nervous system disorders and owns a subsidiary selling hemp seed oil products on Amazon.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a new international patent application in collaboration with Clearmind Medicine Inc. This patent covers a combination therapy designed to address obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The therapy leverages the pharmacological profile of MEAI and the properties of PEA. This development is part of an ongoing collaboration between SciSparc and Clearmind, which has already resulted in multiple patent applications. SciSparc focuses on developing cannabinoid-based pharmaceuticals and has several drug development programs targeting disorders like Tourette Syndrome and Alzheimers disease.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the filing of a new international patent application under the Patent Cooperation Treaty. The patent covers a novel combination therapy using MEAI and Palmitoylethanolamide (PEA) to address obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). These conditions affect a significant portion of the global population, with limited treatment options currently available. Clearminds approach leverages the pharmacological profile of MEAI and the anti-inflammatory properties of PEA. This development is part of Clearminds collaboration with SciSparc Ltd., aiming to provide innovative solutions for unmet medical needs. The company holds a robust intellectual property portfolio and continues to seek additional patents.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company specializing in cannabinoid-based therapies, announced that it has regained compliance with Nasdaqs listing requirements. The company received a notice from Nasdaq confirming that its ordinary shares maintained a minimum bid price of $1.00 per share for 10 consecutive business days, resolving a previous deficiency issue. SciSparc is focused on developing treatments for central nervous system disorders and rare diseases, with ongoing programs targeting conditions such as Tourette Syndrome, Alzheimers disease, autism, and status epilepticus. The company also has a subsidiary involved in selling hemp seed oil products on Amazon. This compliance achievement is a positive development for SciSparc, supporting its continued presence on the Nasdaq exchange.

growth-negative

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a one-for-twenty-one reverse share split of its ordinary shares, effective July 3, 2025. The reverse split, approved by shareholders in October 2024, will reduce the number of outstanding shares from approximately 11.2 million to 534,600. The companys shares will continue trading on Nasdaq under the symbol SPRC with a new CUSIP number. The reverse split will not alter the percentage of ownership for shareholders, except for minor changes due to fractional shares, which will be rounded to the nearest whole share. The exercise price and number of shares for outstanding options and warrants will be adjusted proportionately.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced the publication of a Japanese divisional patent for a novel pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA). This combination aims to enhance pain and fever relief with lower doses and fewer side effects compared to paracetamol alone. The innovation could offer a safer alternative for pain management, minimizing risks like liver damage. SciSparc focuses on developing therapies for central nervous system disorders and rare diseases, with ongoing programs for conditions like Tourette Syndrome and Alzheimers disease. The announcement highlights SciSparcs commitment to advancing cannabinoid pharmaceuticals and enhancing treatment options.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of a European patent application for its proprietary psychedelic-based combination therapy aimed at treating cocaine addiction. This patent strengthens Clearminds global intellectual property portfolio and supports its strategic focus on addiction treatment. The therapy, which includes MEAI and certain N-Acylethanolamines, has shown promising preclinical results in reducing cocaine cravings without affecting natural reward responses. The patent is part of Clearminds collaboration with SciSparc Ltd. to explore the potential of MEAI and PEA-based technologies for treating central nervous system disorders. This development marks a significant milestone in Clearminds mission to develop effective, non-addictive therapies for substance use disorders.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a collaboration with Clearmind Medicine Inc. that resulted in a European patent application for a treatment targeting cocaine addiction. The treatment combines Clearminds MEAI and SciSparcs Palmitoylethanolamide. Preclinical trials showed promising results, with MEAI reducing cocaine-seeking behavior without affecting natural reward responses. This collaboration adds to multiple patent applications filed globally. SciSparc focuses on cannabinoid-based pharmaceuticals and is involved in drug development programs for various disorders. Clearmind, a psychedelic pharmaceutical biotech, aims to develop and commercialize psychedelic-derived therapeutics.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a collaboration with Clearmind Medicine Inc. to file a new international patent application for a treatment targeting eating disorders such as anorexia and bulimia. The treatment combines 3-Methylmethcathinone (3-MMC) with SciSparcs Palmitoylethanolamide (PEA) to address the neurobiological and psychological factors of these disorders. This collaboration represents a strategic move to expand SciSparcs portfolio in cannabinoid pharmaceuticals and psychedelic-derived therapeutics. The partnership with Clearmind Medicine, a clinical-stage psychedelic pharmaceutical company, aims to leverage both companies expertise in developing innovative treatments for mental health conditions.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a significant development in its collaboration with Clearmind Medicine Inc. The partnership has resulted in a patent application published by the South Korean Intellectual Property Office for a combination treatment targeting cocaine addiction. The treatment combines Clearminds MEAI and SciSparcs PEA, showing promising preclinical trial results. The study demonstrated that MEAI effectively reduces cocaine-seeking behavior without affecting natural reward responses. This collaboration adds to multiple patent applications filed globally, enhancing SciSparcs portfolio in cannabinoid pharmaceuticals. SciSparc is actively developing therapies for various disorders, including Tourette Syndrome and Alzheimers disease.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of a patent by the Korean Intellectual Property Office for its combination therapy of MEAI and N-Acylethanolamines aimed at treating cocaine addiction. The patent is based on preclinical trials showing MEAIs effectiveness in reducing cocaine cravings without affecting natural reward responses. This development is part of Clearminds collaboration with SciSparc Ltd., focusing on combining Clearminds psychedelic treatment with SciSparcs PEA. Clearmind is committed to expanding its intellectual property portfolio, which currently includes 19 patent families and 31 granted patents, as it continues to develop psychedelic-derived therapeutics for under-treated health issues.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has signed a definitive agreement to sell its entire ownership interest in MitoCareX Bio Ltd to N2OFF, a publicly-traded company in the U.S. SciSparc will sell shares for $700,000 and exchange its remaining shares for common stock in N2OFF, receiving up to 40% of N2OFFs fully diluted capital stock. The transaction is subject to N2OFF shareholder approval. MitoCareX will become a wholly owned subsidiary of N2OFF, and SciSparc will receive additional N2OFF stock based on milestone achievements. N2OFF will invest $1 million in MitoCareX post-closing, and Dr. Silberman will continue as CEO under a revised agreement.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has entered into a loan agreement with AutoMax Motors Ltd to provide a $2 million loan to support AutoMaxs business expansion into electric vehicles. This loan is part of a larger financial arrangement related to a merger agreement signed in April 2024, under which SciSparc will acquire 100% of AutoMax. The merger aims to expand SciSparcs business into the automotive sector. The loan bears an 8% annual interest rate and will be repaid in monthly installments. The merger is subject to customary closing conditions, including shareholder approvals. SciSparc focuses on developing cannabinoid-based pharmaceuticals and owns a subsidiary selling hemp seed oil products.

growth-positive

N2OFF Inc., a clean tech company, announced its acquisition of MitoCareX Bio Ltd., a biotech firm specializing in cancer therapeutics. The acquisition involves purchasing shares from SciSparc Ltd and exchanging shares with other sellers, resulting in MitoCareX becoming a wholly owned subsidiary of N2OFF. The agreement includes a financial commitment from N2OFF to support MitoCareXs operations, with an initial investment of $1 million. The acquisition aims to leverage MitoCareXs expertise in drug discovery targeting the mitochondrial SLC25 protein family to develop novel cancer therapies. The transaction is subject to stockholder approval and includes milestone-based stock issuances for the sellers.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a settlement regarding a lawsuit filed against six former directors. The lawsuit involved allegations of fiduciary breaches related to a prior acquisition. As part of the settlement, SciSparc will receive $411,000 and will terminate a disputed licensing agreement with Dekel Pharmaceuticals. SciSparc retains exclusive global rights to its IP portfolio, while Dekel assumes ownership of unrelated patent applications. This resolution allows SciSparc to focus on its core development programs, which include cannabinoid-based therapies for conditions like Tourette Syndrome and Alzheimers disease. The settlement is seen as a positive development for the company, allowing it to continue its clinical trials and development efforts without legal distractions.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced a collaboration with Clearmind Medicine Inc., a biotechnology company focused on psychedelic-derived therapeutics. The collaboration has led to the publication of a patent application in Mexico for a combination therapy involving MDMA and N-Acylethanolamines. This innovative therapy aims to address binge behaviors such as alcohol consumption and eating. The partnership has resulted in 13 patents being filed in the U.S. and other jurisdictions. SciSparc is focused on developing therapies for disorders of the central nervous system, with ongoing programs targeting conditions like Tourette Syndrome and Alzheimers disease.

growth-negative

SciSparc Ltd, a clinical-stage pharmaceutical company, has been granted an additional 180-day period by Nasdaq to regain compliance with the minimum bid price rule. The company had previously failed to meet the $1.00 minimum bid price per share requirement and was initially given until January 13, 2025, to comply. After failing to meet this deadline, SciSparc requested and received an extension until July 14, 2025. The company plans to address the deficiency, potentially through a reverse share split. This notification does not immediately affect the listing or trading of SciSparcs shares on Nasdaq, which continue to trade under the symbol SPRC.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a significant development involving its partner AutoMax Motors Ltd. AutoMax received its first shipment of electric vehicles from JAC Motors, a Chinese automotive company, marking a milestone in its direct import and distribution operations in Israel. This aligns with AutoMaxs strategy to meet the growing demand for sustainable transportation. SciSparc has financially supported AutoMax, facilitating its transaction with JAC Motors. Additionally, AutoMax entered into a merger agreement with SciSparc in April 2024, which, upon completion, would allow SciSparc to expand into the automotive sector. The merger is pending shareholder approval from both companies.

growth-positive

SciSparc, through its joint venture MitoCareX Bio with Dr. Alon Silberman, is expanding its research and development efforts to include pancreatic cancer. This decision follows positive in-vitro results using pancreatic cancer cell lines. MitoCareX has previously developed a computationally advanced drug discovery platform that screened millions of small molecules, identifying several with potential anti-cancer properties. The expansion into pancreatic cancer research marks a significant step in MitoCareXs therapeutic ambitions, which previously focused on non-small cell lung cancer. This development is expected to positively impact SciSparc by broadening its research scope and potential treatment offerings.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced that its joint venture, MitoCareX Bio Ltd, is expanding its R&D efforts into pancreatic cancer following promising in-vitro results. MitoCareX focuses on drug discovery targeting the mitochondrial SLC25 protein family and has developed a computational drug discovery platform. The company is also working on a predictive AI model to explore broader chemical spaces for novel anti-cancer treatments. This expansion into pancreatic cancer, alongside its existing focus on non-small cell lung cancer, marks a significant growth in its therapeutic ambitions. SciSparc continues to develop cannabinoid-based pharmaceuticals for various disorders and holds a controlling interest in a subsidiary selling hemp seed oil products.

growth-positive

SciSparc Ltds stock saw a significant increase in trading volume following the announcement of its ongoing collaboration with Clearmind Medicine Inc. The collaboration focuses on researching combination therapies using psychedelic molecules and N-acylethanolamines. Clearmind has filed multiple patents related to this research. Additionally, SciSparc received FDA approval for its investigational new drug, allowing it to proceed to a Phase 2b trial for treating Tourette Syndrome. This development has positively impacted SciSparcs stock price, which rose by 152.90% on Monday.

growth-negative

The article discusses the performance of health care stocks during Mondays premarket hours. It highlights that health care stocks were generally higher, but specifically mentions that SPRC experienced a decline of 10.13% and GDTC fell by 4.03%. The article is part of a premium news service, suggesting that more detailed analysis is available to subscribers. The focus is on stock performance within the health care sector, with no specific mention of partnerships, acquisitions, or other corporate activities.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced its ongoing collaboration with Clearmind Medicine Inc., focusing on developing innovative combination therapies using psychedelic molecules and N-acylethanolamines. Clearmind has submitted a European patent application for a therapy targeting binge behaviors. The collaboration has resulted in thirteen patents filed in the US and other jurisdictions. SciSparc is developing cannabinoid-based therapies for disorders like Tourette Syndrome and Alzheimers disease. Clearmind, a clinical-stage psychedelic biotech, aims to commercialize psychedelic-based compounds for mental health issues. Both companies are expanding their intellectual property portfolios through patents.

growth-positive

SciSparc, an Israel-based specialty clinical-stage pharmaceutical company, has received a renewal from the Israeli Medical Cannabis Agency for its clinical trial of SCI-210, targeting pediatric patients with autism spectrum disorder (ASD). The trial, conducted in collaboration with Soroka University Medical Center, involves 60 individuals aged five to 18 and aims to assess the safety and efficacy of a therapy combining cannabidiol (CBD) and CannAmide. The approval, valid for 30 days, is expected to be extended with final consent from the Israeli police department. This renewal is crucial for the continuation of the study, which could lead to improved treatment options for ASD. SciSparc plans to commercialize the therapy in Israel and expand internationally, pending regulatory approvals.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced the renewal of its approval from the Israeli Medical Cannabis Agency to conduct a clinical trial for SCI-210 in children with autism spectrum disorder. This renewal allows SciSparc to continue its trial, which is a double-blind, randomized, and placebo-controlled study involving 60 children aged 5 to 18. The trial aims to evaluate the efficacy and safety of SCI-210, a combination of CBD and CannAmide™, compared to standard CBD monotherapy. The study is conducted at Soroka University Medical Center in Israel and is expected to generate valuable data for advancing treatment options for ASD. SciSparc plans to commercialize SCI-210 in the Israeli market first, with potential international expansion.

growth-positive

SciSparc announced a significant development in its strategic expansion into the automotive sector through a merger agreement with AutoMax Motors, an automotive importer and distributor in Israel. AutoMax received its first shipment of vehicles from Anhui Jianghuai Automobile Group Co., a Chinese automotive manufacturer, marking a milestone in its import and distribution operations. This follows regulatory approvals and agreements signed earlier this year with JAC Motors. SciSparc has provided financial support to AutoMax, facilitating this transaction. The merger, subject to shareholder approval, is part of SciSparcs growth strategy to expand into the automotive sector. This development is expected to enhance AutoMaxs marketing and sales activities for JAC Motors vehicles across Israel.

growth-positive

SciSparc Ltd. shares surged after announcing that AutoMax Motors Ltd., with which it has a merger agreement, received its first $13 million shipment of JAC Motors vehicles. This milestone marks the beginning of AutoMaxs direct import and distribution operations in Israel, supported financially by SciSparc. The merger, announced in April 2024, aims to expand SciSparc into the automotive sector, pending shareholder approval. Additionally, SciSparc plans to spin off its pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals Inc. The companys shares increased by 256% in premarket trading, reflecting positive market sentiment towards these strategic moves.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced a significant development in its merger with AutoMax Motors Ltd, an automotive importer in Israel. AutoMax has received its first shipment of vehicles from JAC Motors, marking a milestone in its direct import and distribution operations. This development follows regulatory approvals and positions AutoMax to begin marketing JAC Motors vehicles in Israel. SciSparc has financially supported AutoMax, facilitating this transaction. The merger agreement, initiated in April 2024, is part of SciSparcs strategy to expand into the automotive sector, pending shareholder approvals. SciSparc continues to focus on cannabinoid pharmaceuticals, with ongoing drug development programs and a subsidiary selling hemp seed oil products on Amazon.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced an amendment to its letter of intent to spin off its pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals Inc. through a reverse merger with Miza III Ventures Inc. The transaction, valued at approximately $11.6 million for SciSparcs assets, will result in SciSparc holding a controlling interest in Miza, ranging from 75% to 84.53%. The merger aligns with SciSparcs strategy to create shareholder value and follows a previously announced merger plan with AutoMax Motors Ltd. SciSparcs pharmaceutical portfolio includes treatments for Tourette syndrome, Alzheimers disease, and autism, with ongoing clinical trials. The definitive agreement is expected by March 31, 2025, with the transaction closing by April 30, 2025.

growth-positive

Jeffs’ Brands, a data-driven e-commerce company operating on the Amazon Marketplace, announced that its subsidiary, SciSparc Nutraceuticals, has received trademark registration for its Wellution brand. Wellution, which offers a range of hemp-based wellness and personal care products, now has intellectual property protection for its non-medicated skin care and hair care products. This development is expected to enhance the brands market position and protect its innovative offerings. The announcement also highlights Jeffs’ Brands partnership with Deliverz.AI for a U.S. robotics venture, as well as other strategic initiatives such as a patent licensing agreement and a reverse stock split.

growth-positive

Israeli pharmaceutical company SciSparc has received approval from the US FDA to begin a Phase IIb clinical trial of SCI-110 for treating Tourette syndrome in adults aged 18 to 65. The trial will be conducted at Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center. The primary goals are to assess the efficacy, safety, and tolerability of SCI-110. SciSparc CEO Oz Adler highlighted the unmet medical need for effective Tourette syndrome treatments and expressed optimism based on promising results from a previous Phase IIa trial.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced that the FDA has approved its IND application for its drug candidate SCI-110 to proceed with Phase IIb clinical trials for treating Tourette Syndrome (TS). This approval marks a significant milestone for the company. The trial will be conducted at three leading medical centers: Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center. The trial aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adult patients. Previous Phase IIa trials showed promising results, with a notable reduction in tic severity. SciSparc focuses on developing cannabinoid-based therapies for central nervous system disorders.

growth-positive

SciSparc Ltd. announced a non-binding letter of intent to sell its entire ownership interest in MitoCareX Bio Ltd. to a publicly-traded U.S. company. The transaction is valued at $5 million, with potential milestone payments increasing it to $7 million. SciSparc will initially receive $700,000 in cash for 27% of its stake, followed by shares valued at $8 million for the remaining 73%. The valuation of MitoCareX has increased by 47% since SciSparcs initial investment. This move aligns with SciSparcs strategy to enhance shareholder value.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced that the FDA has approved its investigational new drug application for SCI-110, allowing Phase IIb clinical trials for treating Tourette Syndrome to proceed. The trials will be conducted at Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center. This milestone follows the companys submission of the IND application a month ago and marks a significant step in developing effective treatments for central nervous system disorders. The trial aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adult patients.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, has submitted an Investigational New Drug application to the U.S. FDA for a phase IIb clinical trial of its drug candidate SCI-110 for treating Tourette Syndrome. The trial will be conducted at three leading medical centers: Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center. The trial aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adult patients. The primary efficacy measure will be tic severity change, and the primary safety measure will be the frequency of serious adverse events. The company has already secured necessary approvals from relevant authorities.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced the publication of an international patent application for an innovative drug combination treatment in collaboration with Clearmind Medicine Inc. The treatment focuses on mental health and addiction care, combining Ibogaine with N-Acylethanolamines. This collaboration has resulted in thirteen patents filed by Clearmind in various jurisdictions. SciSparc is engaged in developing therapies for disorders of the central nervous system, including treatments for Tourette Syndrome, Alzheimers disease, autism, and status epilepticus. Clearmind, a clinical-stage psychedelic pharmaceutical biotech company, focuses on developing novel psychedelic-derived therapeutics.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced an additional loan of $1.85 million to AutoMax Motors Ltd, bringing the total bridge loan amount to $4.25 million. This loan is part of a broader merger agreement between SciSparc and AutoMax, which includes a fixed charge security interest on AutoMax’s shares. Additionally, AutoMax, through its subsidiary AutoMax Leasing Ltd, signed a direct import agreement with JAC Motors, a major Chinese automobile manufacturer. The merger and loan are expected to positively impact SciSparcs growth by expanding its portfolio and partnerships.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced a significant milestone in its ongoing collaboration with Clearmind Medicine Inc. The two companies have published an international patent application for a novel combination therapy involving MDMA and N-Acylethanolamines, aimed at enhancing safety and efficacy in mental health and addiction treatments. This collaboration has led to the filing of thirteen patents in various jurisdictions. The partnership aims to address FDA concerns regarding MDMA safety and unlock its full potential in clinical settings. This development is seen as a promising path forward for treating mental health disorders and addictions.

growth-positive

Clearmind Medicine Inc., a clinical-stage biotech company, announced the publication of an international patent application for its innovative combination of MDMA with N-Acylethanolamines. This patent is part of an ongoing collaboration with SciSparc Ltd., focusing on developing treatments for mental health and addiction. The collaboration has resulted in thirteen patents filed in the U.S. and other jurisdictions. The new combination aims to enhance the safety and efficacy of MDMA by reducing its dosage while maintaining therapeutic benefits. This development reflects Clearminds commitment to pioneering new treatments for under-treated health problems.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced its ongoing collaboration with Clearmind Medicine Inc. Clearmind has published a patent application for innovative combinations of ketamine and N-acylethanolamines. The collaboration focuses on developing treatments for addictions, weight loss, and mental health disorders using SciSparc’s Palmitoylethanolamide (PEA) and Clearmind’s psychedelic molecule, MEAI. Thirteen patents have been filed related to this collaboration. The FDA approved a ketamine derivative for treating depression under strict guidelines. SciSparc aims to improve treatment outcomes while minimizing adverse effects. The announcement was made on August 29, 2024.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced an Exclusive Patent License Agreement with Polyrizon Ltd for its SCI-160 program, aimed at pain treatment. Under this agreement, SciSparc will receive $3 million in Polyrizon securities and potentially $3 million in milestone fees, along with royalties. SCI-160, a synthetic combination of cannabinoids and N-acylethanolamines, has shown promising results in pre-clinical studies for pain management without significant side effects. The agreement is expected to positively impact SciSparcs growth by leveraging Polyrizons capabilities for further development and sublicensing.

growth-positive

Israel-based pharma company SciSparc has submitted an investigational new drug (IND) application to the US FDA for a Phase IIb clinical trial of its drug candidate SCI-110 to treat Tourette Syndrome (TS). The trial will assess the safety, efficacy, and tolerability of daily oral doses of SCI-110 in adults aged 18-65. It will take place at three centers: Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center. Institutional Review Board approvals have been obtained from all sites. The primary efficacy endpoint is the change in tic severity at weeks 12 and 26 compared to baseline.

growth-positive

SciSparc has received final approval from Tel Aviv Sourasky Medical Center in Israel to initiate a Phase IIb trial of its drug SCI-110 for the treatment of Tourette’s Syndrome (TS). The trial aims to assess the efficacy, safety, and tolerability of a daily oral dose of SCI-110 in adult patients aged 18 to 65. The trial will be led by Dr. Tanya Gurevich at the Tel Aviv Sourasky Medical Center and will include multiple sites, including Yale Child Study Center at Yale School of Medicine. SciSparc CEO Oz Adler expressed optimism about the potential of SCI-110 to help TS patients globally.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, has announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its phase IIb clinical trial for its proprietary SCI-110 for the treatment of Tourette Syndrome (TS). The trial will be conducted at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel. The company has already secured the necessary approvals from all three clinical sites.

growth-positive

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, announced that MitoCareX Bio Ltd., the Company’s venture with Dr. Alon Silberman, has appointed Professor Nir Peled to its scientific advisory board. Professor Peled is a distinguished expert in thoracic oncology and his appointment is expected to significantly contribute to the companys advancement in discovering and developing innovative cancer treatments. MitoCareX is currently focusing on drug discovery and development of therapeutics for cancer and other life-threatening conditions by targeting the mitochondrial SLC25 protein family.

growth-positive

Israel-based pharmaceutical company SciSparc has signed an exclusive patent licence agreement with Polyrizon for the out-licensing of its SCI-160 programme for pain treatment. Polyrizon will receive a sole, royalty-bearing worldwide licence for developing and sublicensing the assets. In return, SciSparc will receive Polyrizon securities valued at $3m, along with potential milestone cash payments of $3m, contingent upon achieving specific development goals. SciSparc will also earn royalties from the commercialisation of the therapy.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced that the first five patients have been enrolled and dosed into its ongoing clinical trial for SCI-210, a treatment for Autism Spectrum Disorder (ASD), at the Soroka Medical Center in Israel. The trial will enroll 60 subjects between the ages of five and 18 for 20 weeks. The company aims to sell SCI-210 first in Israel and then in other countries, subject to obtaining the requisite regulatory approvals.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has signed an Exclusive Patent License Agreement with Polyrizon Ltd for the out-licensing of its SCI-160 program for pain treatment. Polyrizon will receive an exclusive, royalty-bearing global license to develop and sublicense the Assets. In return, SciSparc will receive Polyrizon securities valued at $3 million, potential milestone fees of approximately $3 million in cash, and royalties if certain development milestones are met.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced progress with its merger agreement with AutoMax Motors Ltd. The Jerusalem District Court in Israel has approved AutoMax’s petition to convene special class meetings of its shareholders to approve the merger with SciSparc. Additionally, the company entered into an addendum to the merger agreement, deferring the right to terminate the merger agreement if the merger was not consummated by August 30, 2024, to November 30, 2024.

growth-positive

SciSparc Ltd and Clearmind Medicine have been collaborating since 2022 to develop effective treatments for obesity and metabolic syndrome. The partnership combines SciSparc’s Palmitoylethanolamide (PEA) and Clearmind’s 5-methoxy-2-aminoindane (MEAI). A recent study has shown promising results, with the treatment significantly reducing weight loss in diet-induced obesity in mice. The collaboration has led to multiple patent applications, aiming to offer safer and more effective therapeutic options. The companies jointly fund various studies and IP related to their collaboration.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced that its venture with Dr. Alon Silberman, MitoCareX Bio Ltd, has validated the significant involvement of its target SLC25 carrier protein in Non-Small Cell Lung Cancer (NSCLC) cells. MitoCareX demonstrated this discovery using genetic manipulations and 3D spheroid systems. The NSCLC market is projected to reach a value of $59.77 billion by 2030. MitoCareX is working towards creating a predictive AI model to uncover more novel anti-cancer small molecule scaffolds that target its SLC25 protein of interest.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, has signed a non-binding letter of intent with an undisclosed biotechnology company for the out-licensing of its SCI-160 program for pain treatment. The biotech company will receive exclusive, royalty-bearing global licenses to develop and sublicense the Assets. In return, SciSparc will receive $3 million in ordinary shares and pre-funded warrants of the biotech company, with potential for additional payments and execution fees of approximately $3 million in cash if certain milestones are met.

growth-negative

SciSparc Ltd, a clinical-stage pharmaceutical company, has received a notice from Nasdaq stating that it is not in compliance with the minimum bid price requirement for continued listing. The companys shares need to maintain a minimum bid price of $1.00 per share. SciSparc has been granted a period of 180 days to regain compliance. If it fails to do so, it may be eligible for an additional 180-day compliance period. If the company cannot demonstrate compliance by the allotted compliance period(s), its shares are subject to delisting.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has submitted an additional patent application with the US Patent and Trademark Office as part of its ongoing collaboration with Clearmind Medicine Inc. The patent application is for a novel proprietary composition of Palmitoylethanolamide, the active ingredient of SciSparc’s proprietary CannAmide with Clearmind’s innovative MEAI compound for treating metabolic syndrome and obesity. The global obesity treatment market size was $15 billion in 2022 and is expected to grow at a compound annual growth rate of 10.0% during the forecast period.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has signed a non-binding letter of intent to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals Inc. The agreement is to be negotiated with Miza III Ventures Inc., a publicly traded company on the Toronto Stock Exchange Venture in Canada. The agreement is based on the approximate total USD 3.3 million enterprise value of Miza and an approximate USD 11.6 million value of SciSparc’s assets. Following the transaction, SciSparc would hold a controlling interest in Miza.

Growth-Positive

SciSparc has signed a non-binding letter of intent to spin off its advanced clinical stage pharmaceutical portfolio. The news was reported by PremiumMT Newswires on July 8, 2024.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, has been granted a patent by the European Patent Office for Compositions and Methods of Potentiating Antimicrobials, adding to its existing patent granted by the United States Patent and Trademark Office. This strengthens SciSparcs intellectual property portfolio and its position in the global pharmaceutical market. The patent relates to pharmaceutical compositions comprising antibiotics and cannabinoids, used in treating and preventing microbe biofilm formation and microbe-induced pathologies. This is significant in the context of antimicrobial and antibiotic resistance.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced a merger agreement with AutoMax Motors Ltd, a leading vehicle importer in Israel. According to the agreement, SciSparc will acquire 100% of AutoMax and establish a new wholly-owned Israeli subsidiary, which will then merge with AutoMax. The acquisition is part of SciSparcs strategy to maximize shareholder value and will not affect the companys ongoing business operations. The deal is subject to regulatory approvals and shareholder approvals from both companies.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced a collaboration with Clearmind Medicine Inc. to develop therapies for disorders and rare diseases of the central nervous system. As part of the collaboration, Clearmind has submitted a patent application for a novel proprietary composition of its MEAI compound with the active ingredient of SciSparcs proprietary CannAmide for preventing and treating depression. The global depression and anxiety disorders treatment market is expected to reach USD 41.83 billion by 2034.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced that its venture with Dr. Alon Silberman, MitoCareX Bio Ltd, has virtually screened millions of small molecules using its advanced drug discovery platform. This has resulted in the identification of several molecules that could be used for potential anti-cancer treatments. MitoCareX is also working towards creating a predictive AI model to navigate broader chemical spaces more efficiently, with the goal of uncovering more novel anti-cancer scaffolds that target its SLC25 protein of interest.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has been granted a patent by the Canadian Intellectual Property Office for its core technology, the combination of cannabinoids and n-acylethanolamines. The patent is designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits. The patent grant adds to the companys patent portfolio, supporting the innovation of SciSparc’s technologies. The patent covers the compositions and methods for potentiating therapeutic effects and reducing the side-effects of selected cannabinoids initially discovered in the cannabis plant.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, has announced the successful dosing of the first patient in its SCI-210 clinical trial for pediatric patients with Autism Spectrum Disorder (ASD) at the Soroka Medical Center. The SCI-210 treatment combines cannabidiol-rich oil and CannAmide, SciSparcs proprietary palmitoylethanolamide-based tablets. The trial aims to evaluate the safety, tolerability, and efficacy of SCI-210 in comparison to CBD monotherapy for the treatment of ASD. The study will span 20 weeks and enroll 60 children.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced that its venture with Dr. Alon Silberman, MitoCareX Bio Ltd, has made significant progress in drug discovery and the development of cancer therapeutics. MitoCareX has virtually screened millions of small molecules using its advanced drug discovery platform, identifying several potential anti-cancer treatments. MitoCareX is also working on creating a predictive AI model to navigate broader chemical spaces more efficiently and uncover more novel anti-cancer scaffolds that target the SLC25 protein of interest.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced the enrollment of the first patient in a clinical trial for SCI-210, a treatment for children with autism spectrum disorder (ASD). The company plans to sell SCI-210 in Israel and other countries, pending regulatory approvals. The double-blind, randomized, and placebo-controlled study will use SciSparcs proprietary SCI-210, a combination of cannabidiol (CBD) and CannAmide™. The trial aims to enroll 60 subjects between the ages of 5 and 18 for 20 weeks to assess how SCI-210 therapy compares to standard CBD treatment in managing ASD symptoms.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced that its core-technology patent has been granted and validated in several European countries. The patent covers combinations of cannabinoids and n-acylethanolamines, aligning with the companys proprietary technology designed to enhance the safety of cannabinoids. The patent was granted due to the unique composition of cannabinoids and n-acylethanolamines and their use in preventing and treating a variety of cannabinoid-treated conditions. This adds to the companys patent portfolio, supporting the innovation of SciSparc’s technologies.

growth-positive

SciSparc Ltd, a specialty clinical-stage pharmaceutical company, has received patent approval for its proprietary combination of opioids and n-acylethanolamines for pain treatment. The patent has been granted by the Canadian Intellectual Property Office. The company believes that its technology will potentially improve the therapeutic effect of opiates in lower doses, reducing their addictive potential. The global opioid market was valued at $22.8 billion in 2022 and is anticipated to grow at a compound annual growth rate of 1.4% from 2023 to 2030.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced the completion of manufacturing and delivery of its SCI-210 treatment for a clinical trial at the Soroka Medical Center. The trial will involve pediatric patients with Autism Spectrum Disorder (ASD). The SCI-210 treatment combines cannabidiol-rich oil and CannAmide, SciSparc’s proprietary palmitoylethanolamide-based tablets. The trial will examine the safety, tolerability, and efficacy of SCI-210, compared to CBD monotherapy, for the treatment of ASD. The company hopes the outcome of the trial will enable commercialization of SCI-210 in Israel.

growth-positive

Clearmind Medicine Inc has submitted three additional patent applications under the international Patent Cooperation Treaty (PCT) in collaboration with SciSparc Ltd. The patents relate to compositions of MDMA, Ibogaine, and Ketamine, each with Palmitoylethanolamide (PEA), the active ingredient of SciSparc’s proprietary CannAmide. These were previously filed as provisional patent applications with the United States Patent and Trademark Office (USPTO). Clearmind now has 27 granted patents and 24 pending patent applications across 15 patent families. Clearmind recently received approval from the Ministry of Health of Israel to commence its phase 1/2a trial for alcohol use disorder patients.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced its ongoing collaboration with Clearmind Medicine Inc. Clearmind has filed three patent applications under the international Patent Cooperation Treaty for novel proprietary compositions of MDMA, ibogaine, and ketamine, each combined with palmitoylethanolamide, the active ingredient of SciSparcs proprietary CannAmide. Eight other applications have been filed by Clearmind with the USPTO for various combinations. The collaboration aims to develop therapies to treat disorders and rare diseases of the central nervous system.

growth-positive

Clearmind Medicine Inc., a biotech company focused on the development of psychedelic-derived therapeutics, has submitted three additional patent applications under the international Patent Cooperation Treaty (PCT) in collaboration with SciSparc Ltd. The patent applications refer to novel proprietary compositions of MDMA, Ibogaine, and Ketamine, each with Palmitoylethanolamide (PEA), the active ingredient of SciSparc’s proprietary CannAmide™. These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office (USPTO).

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced its ongoing collaboration with Clearmind Medicine Inc. Clearmind has filed three patent applications for novel combinations of various compounds, including the active ingredient of SciSparcs proprietary CannAmide™. These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office. SciSparc’s CEO, Oz Adler, expressed his pleasure at the continued collaboration and the expansion of the intellectual property portfolio.

Growth-Positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has submitted three patent applications under the international Patent Cooperation Treaty (PCT). This is part of its ongoing collaboration with SciSparc Ltd., a pharmaceutical company focusing on central nervous system disorders. The patent applications refer to novel combinations of LSD, psilocybin, DMT, and SciSparcs Palmitoylethanolamide (PEA). Clearmind now has 27 granted patents and 24 pending patent applications across 15 patent families. The company aims to commercialize psychedelic-based compounds as regulated medicines, foods, or supplements.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced the initiation of patient recruitment for its clinical trial of SCI-210, a treatment for autism spectrum disorder (ASD), at Soroka Medical Center in Israel. The company plans to enroll 60 subjects between the ages of five and 18 for a 20-week study. Following the trial, SciSparc aims to commercialize SCI-210 first in Israel and then in other countries, subject to regulatory approvals. The trial is a significant milestone for the company as it aligns with their mission to develop novel therapies to improve human health.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, has entered into a standby equity purchase agreement with YA II PN, Ltd., a fund managed by Yorkville Advisors Global, LP. Under the agreement, YA II PN, Ltd. will purchase up to $20 million of SciSparcs ordinary shares over the next three years. The purchase price will be at a 3% discount of the weighted average price of the companys shares during the three consecutive trading day period commencing on the trading day of the delivery of an advance notice by the company. The proceeds from the potential offering will be used for working capital and other general corporate purposes.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced a bridge loan agreement with a leading vehicle importer company in Israel, with the latter receiving a loan of $1.4 million. This move is in line with SciSparcs intent to acquire the vehicle importer company. The agreement, signed on January 16, 2024, states that the principal amount of the loan will bear an interest rate of 7% per annum, compounded annually. The repayment of the loan will be due at the earlier date of the acquisition closing or July 15, 2024.

growth-positive

Clearmind Medicine Inc., a biotech company focused on the development of psychedelic-derived therapeutics, has filed six US patent applications in collaboration with SciSparc Ltd. The patents are for unique combinations of future psychedelic-based compounds, aimed at providing safer and more effective treatments for patients with mental health disorders. The patent applications are part of Clearminds commitment to strengthen its IP portfolio and broaden the therapeutic psychedelic toolbox. Clearmind has a broad IP footprint in the psychedelic space, with 51 patents in 15 utility patent families. Any assets generated from the collaboration will be jointly owned by Clearmind and SciSparc.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, reflects on its successful collaboration with Clearmind Medicine Inc in 2023. The collaboration resulted in six provisional patent applications filed by Clearmind with the US Patent and Trademark Office for unique combinations of future psychedelic-based compounds. The patent applications represent a commitment by SciSparc and Clearmind to offer patients safer and more effective treatments than those available today. The patents are for novel proprietary combinations of various psychedelic compounds, including LSD, psilocybin, DMT, and PEA, the active ingredient of SciSparc’s proprietary CannAmide™.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced that its joint venture with Dr. Alon Silberman, MitoCareX Bio, has achieved its second milestone in drug discovery for cancer treatment. The milestone was achieved by developing multiple lab screening platforms that screen for and isolate potential anti-cancer drug molecules for pre-clinical studies. As per the agreement, this triggers SciSparc to invest an additional $600,000 into the joint venture. Following this investment, SciSparc will hold 50.1% of the issued and outstanding share capital of MitoCare X Bio.

Growth-Positive

SciSparc Ltd., a clinical-stage pharmaceutical company, announced updates on the negotiation of a non-binding letter of intent with a leading vehicle importer company in Israel. According to the new terms, SciSparc will acquire 100% of the Target Company and establish a new wholly-owned Israeli subsidiary, which would merge with the Target Company. The acquisition is subject to successful completion of due diligence, execution of binding definitive agreements, and compliance with regulatory requirements and approvals.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced successful results from a pre-clinical trial for its obesity and metabolic disorder program. The trial was conducted in collaboration with Clearmind Medicine Inc., a biotech company focused on the development of novel psychedelic-derived therapeutics. The trial aimed to identify the optimal dosage for the combination treatment of palmitoylethanolamide (PEA) and MEAI, and observe its safety and impact on various metabolic and behavioral parameters. The results showed increased metabolic activity, reduced appetite, and enhanced fat oxidation.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, announced successful results from a pre-clinical trial conducted in collaboration with Clearmind Medicine Inc. The trial tested a combination treatment of SciSparcs proprietary CannAmide and Clearminds MEAI molecule for various addictions, obesity, and depression. The trial aimed to identify the optimal dosage for the Combination Treatment and observe its safety and impact on various metabolic and behavioral parameters. The results showed increased metabolic activity, reduced appetite, and enhanced fat oxidation, indicating the treatments efficacy and safety.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, has adopted a limited duration shareholder rights plan to protect the long-term interests of the company and its shareholders. The plan is designed to reduce the likelihood of any entity gaining control or significant influence over SciSparc through the open-market accumulation of the company’s shares without appropriately compensating all SciSparc shareholders. The plan is not in response to a specific takeover threat but is intended to ensure the board has sufficient time to make informed judgments about any attempts to control or significantly influence SciSparc.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has initiated a clinical trial for its proprietary therapy, SCI-210, at Soroka Medical Center in Israel. The therapy, which combines cannabidiol (CBD) and SciSparcs proprietary Palmitoylethanolamide, is aimed at easing the symptoms of Autism Spectrum Disorder (ASD) in children. The trial will enroll 60 participants aged 5-18 years old over a period of 20 weeks to measure how SCI-210 compares to standard CBD treatment in managing ASD symptoms. The company is partnering with the Soroka Medical Center and the National Autism Research Center for this initiative.

Growth-Positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has signed a non-binding letter of intent to merge with a leading vehicle importer company in Israel. The merger is expected to be completed through a reverse triangular merger, with SciSparc establishing a new wholly-owned Israeli subsidiary that would merge with the target company. Upon successful completion of the merger, SciSparc will transfer its pharmaceutical activities to a separate legal entity and explore the possibility of dividend distribution. The merger is subject to the successful completion of due diligence by both parties, the execution of binding definitive agreements, and compliance with regulatory requirements and approvals.

growth-positive

SciSparc Ltd. has announced positive results from its Phase IIa trial for SCI-110, a treatment for agitation in Alzheimers patients. The trial, conducted at the Sophie & Abraham Stuchynski Israeli Alzheimer’s Medical Center, involved 18 patients and demonstrated that SCI-110 was safe, tolerable, and effective. The treatment led to a significant 23% reduction in agitation symptoms and did not cause delirium, oversedation, hypotension, or falls. The companys Chief Technologies Officer, Dr. Adi Zuloff-Shani, expressed excitement over the results, stating they signify a monumental potential in enhancing the lives of Alzheimers patients.

growth-positive

SciSparc Ltd. has announced the initiation of its Phase IIb clinical trial for its proprietary drug candidate, SCI-110, aimed at treating patients suffering from Tourette Syndrome. The trial will be conducted under the regulation of the U.S. Food and Drug Administration, the Federal Institute for Drugs and Medical Devices in Germany, and the Israeli Ministry of Health. The trial will be conducted at Yale University in the USA, Tel Aviv Sourasky Medical Center in Israel, and the Hannover Medical School in Germany. The drug contains Dronabinol, an FDA approved synthetic form of THC, and is designed to stimulate cannabinoid receptors across the central nervous system.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has received approval for its patent application for a combination of opioids and N-Acylethanolamines for pain treatment from IP Australia. The global opioid market, valued at $22.8 billion in 2022, is expected to grow at a CAGR of 1.4% from 2023 to 2030. The companys CEO, Oz Adler, stated that the growing number of granted patents is a testament to the innovative technologies in SciSparcs pipeline. The company is also engaged in drug development programs based on THC and/or non-psychoactive CBD.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, has received a notice of acceptance for its patent application for the Combinations of Cannabinoids and N-Acylethanolamines. The patent was granted by IP Australia and adds to the collection of patents previously granted in Europe, the United States, and Japan. The patent aligns with the companys core technologies designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits. The company is currently engaged in drug development programs based on THC and/or non-psychoactive CBD.

Growth-Positive

SciSparc Ltd. has announced the closing of its private placement with an institutional investor, raising approximately $5.026 million. The company issued 1,930,108 units, each consisting of two Pre-Funded Warrants, which have an exercise price of $0.001 and a term of five years. Aegis Capital Corp. acted as the exclusive placement agent for the private placement. The securities were sold in a private placement exempt from the registration requirements of the Securities Act of 1933. SciSparc is a specialty clinical-stage pharmaceutical company focused on cannabinoid pharmaceuticals.

growth-positive

SciSparc Ltd. has announced a securities purchase agreement with an institutional investor to raise approximately $5.026 million through a private placement. The company will issue an aggregate of 1,930,108 units, each unit consisting of two Pre-Funded Warrants. The closing of the private placement is expected to occur on or about October 13, 2023. Aegis Capital Corp. is acting as the exclusive placement agent for the private placement. The funds raised will be used to enhance the companys portfolio of technologies and assets based on cannabinoid pharmaceuticals.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, has announced the initiation of a pivotal clinical trial for its drug candidate, SCI-210, designed to control symptoms of Autism Spectrum Disorder (ASD). The trial will be conducted at the Soroka University Medical Center and is designed as a randomized, double-blind, placebo-controlled trial with a cross-over study. The trial will span 20 weeks and involve 60 children between 5-18 years old. The company has partnered with the National Autism Research Center for the trial. The CEO of SciSparc expressed optimism that SCI-210 could be a game-changer in ASD treatment.

Neutral

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced a reverse share split of its issued and outstanding ordinary shares at a ratio of 1-for-26. The split is expected to be implemented after market close on September 27, 2023. Post-split, the companys ordinary shares will begin trading on the Nasdaq Capital Market under the existing trading symbol SPRC. The reverse split will adjust the number of issued and outstanding ordinary shares from approximately 13.5 million to around 521,090. No fractional ordinary shares will be issued as a result of the reverse split.

Neutral

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced a reverse share split of its issued and outstanding ordinary shares at a ratio of 1-for-26. The shares will begin trading on the Nasdaq Capital Market on a post-split basis from September 28, 2023. The reverse share split was approved by the companys shareholders at the annual meeting held on August 18, 2023. The companys authorized share capital will not be adjusted under the companys articles of association. No fractional ordinary shares will be issued as a result of the reverse split.

Growth-Positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has engaged Rosario Capital Ltd, an Israeli investment bank, to identify potential opportunities for a strategic transaction. This follows the companys announcement in June 2022 that its board of directors had resolved to initiate a process to review potential strategic transactions to maximize shareholder value. Rosario Capital will seek and evaluate potential strategic transactions on behalf of the company, including additional investments in innovative companies, a strategic partnership, or the licensing of one or more of the company’s proprietary technologies or indications.

Neutral

SciSparc Ltd., a clinical-stage pharmaceutical company, has been granted an additional 180-day compliance period by Nasdaq to regain compliance with Nasdaq’s minimum bid price rule. The company had previously been informed that it no longer met the minimum $1.00 bid price per share requirement. The current notification from Nasdaq has no immediate effect on the listing or trading of the company’s ordinary shares, which will continue to trade on the Nasdaq Capital Market under the symbol “SPRC.”

growth-positive

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, has announced the initiation of its Phase IIb Clinical Trial for its proprietary SCI-110 for the treatment of Tourette Syndrome at the Tel Aviv Sourasky Medical Center in Israel. The trial is based on the positive data results received from the single arm Yale School of Medicine study using SCI-110 for TS. The trial will be conducted at three global leading centers of excellence: the Yale Child Study Center at the Yale School of Medicine in Connecticut, USA, the Hannover Medical School in Hannover, Germany, and at the Tel Aviv Sourasky Medical Center in Israel.

growth-positive

Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. SciSparc is a specialty clinical-stage pharmaceutical company focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. They are currently engaged in drug development programs for various treatments. The company also owns a subsidiary that sells hemp seeds oil-based products on Amazon.com Marketplace. Aegis Capital Corporation, the wealth management and investment banking firm, has been providing corporate finance and advisory services since 1984. They offer a full range of products and services, including investment banking and wealth management.

growth-positive

SciSparc Ltd. has closed a firm commitment underwritten public offering, raising approximately $1.3 million before deductions. The offering consisted of 6,500,000 ordinary shares at a price of $0.20 per share. The company plans to use the net proceeds primarily for working capital. Aegis Capital Corp. has been granted a 45-day option to purchase up to an additional 975,000 ordinary shares to cover over-allotments, potentially raising the total gross proceeds to approximately $1.5 million.

Growth-Positive

SciSparc Ltd. has announced the pricing of a firm commitment underwritten public offering with gross proceeds expected to be approximately $1.3 million. The base offering consists of 6,500,000 ordinary shares at a price to the public of $0.20 per share. The Company intends to use the net proceeds from this offering for working capital. Aegis Capital Corp. has been granted a 45-day option to purchase ordinary shares of up to 15% of the number of ordinary shares sold in the offering to cover over-allotments. The offering is expected to close on August 14, 2023.

Growth-Positive

SciSparc Ltd. announced its plans to offer securities in a firm commitment underwritten public offering. The net proceeds from this offering will be used for working capital. The offering is subject to market conditions and there is no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Aegis Capital Corp. is expected to be granted a 45-day option to purchase additional ordinary shares of up to 15% of the number of ordinary shares sold in the offering solely to cover over-allotments, if any. Aegis Capital Corp. is acting as the sole book-running manager for the offering.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced a new U.S. patent application for the use of the psychedelic molecule 3-MMC and SciSparcs Palmitoylethanolamide to treat dyskinesia and dystonia. This is part of SciSparcs ongoing collaboration with Clearmind Medicine Inc., a biotechnology company focused on the discovery and development of novel psychedelic-derived therapeutics. The patent application was filed by Clearmind with the United States Patent and Trademark Office. The potential treatment for dyskinesia could be a significant addition to SciSparc’s robust IP portfolio and aligns with the companys focus on developing innovative treatments for conditions with unmet need.

growth-positive

Clearmind Medicine Inc has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the treatment of Dyskinesia. The patent application refers to the psychedelic molecule 3-Methylmethcathinone (3-MMC) as a potential treatment for Dyskinesia and expands Clearminds portfolio for innovative molecules, new indications, and treatments. The patent application also includes protection for its unique combination of 3-MMC and SciSparcs Palmitoylethanolamide for Dyskinesia as part of its ongoing collaboration with SciSparc Ltd.

growth-positive

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has filed a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office. The patent application refers to the psychedelic molecule 3-Methylmethcathinone (3-MMC) as a potential treatment for Dyskinesia. The patent application also includes protection for its unique combination of 3-MMC and SciSparcs Palmitoylethanolamide for the treatment of Dyskinesia, as part of its ongoing collaboration with SciSparc Ltd., a specialty clinical-stage pharmaceutical company.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has received approval from the Israeli Medical Cannabis Agency to conduct a clinical trial for its proprietary combination of cannabidiol and CannAmide, SCI-210, in children with autism spectrum disorder (ASD). The company aims to sell SCI-210 first in Israel and then globally, subject to regulatory approvals. The trial will investigate the safety and efficacy of SCI-210 in comparison to CBD monotherapy in treating ASD. The trial was designed in consultation with the National Autism Research Center.

growth-positive

SciSparc Ltd has received approval from the Federal Institute for Drugs and Medical Devices in Germany to conduct a Phase IIb clinical trial using SCI-110 to treat adults with Tourette Syndrome. The trial will be conducted at three global leading centers of excellence. The company believes that SCI-110 has the potential to be a game-changing therapy. The objective of the trial is to evaluate the efficacy, safety, and tolerability of SCI-110 in adult patients. The primary efficacy objective is to assess tic severity change using the Yale Global Tic Severity Scale. The company will provide additional information for the release and stability of SCI-110 within 90 days. SciSparc is a specialty clinical-stage pharmaceutical company focused on developing therapies for disorders of the central nervous system.

growth-positive

SciSparc Ltd. has received Institutional Review Board (IRB) approval for its Phase IIb clinical trial for SCI-110 in subjects suffering from Tourette Syndrome. The trial aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adults with TS. The primary efficacy objective is to assess tic severity change using the Yale Global Tic Severity Scale (YGTSS-R-TTS) as a continuous endpoint. The trial will be led by Dr. Michael H. Bloch from Yale University School of Medicine. Previously, a Phase IIa trial conducted at Yale University showed that SCI-110 was safe and effective. SciSparc is a specialty clinical-stage pharmaceutical company focused on developing therapies for disorders of the central nervous system.

growth-positive

SciSparc Ltd has received Institutional Review Board (IRB) approval for its Phase 2b clinical trial for SCI-110 in subjects suffering from Tourette Syndrome. The trial aims to assess tic severity change using the Yale Global Tic Severity Scale (YGTSS-R-TTS) as an endpoint. The previously conducted Phase 2a trial showed that SCI-110 was safe and effective in reducing tic symptoms. SciSparc shares are up 3.70% in premarket trading.

growth-positive

Clearmind Medicine Inc. has entered into a research agreement with the Hebrew University of Jerusalem to evaluate its combination treatment for obesity and metabolic syndrome. The treatment combines Clearminds MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparcs Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide. The study will be led by Professor Joseph (Yossi) Tam and will evaluate the effect of the combination of MEAI and PEA on food intake, metabolic and activity profiles. Previous pre-clinical studies have shown positive effects of MEAI in treating obesity. Clearminds collaboration with SciSparc has resulted in numerous patent applications related to combination therapies for various disorders. Clearmind Medicine Inc. is a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics.

growth-positive

SciSparc Ltd has announced a research agreement with Clearmind Medicine Inc. and the Hebrew University of Jerusalem to evaluate a proprietary combination treatment for obesity and metabolic syndrome. The treatment combines SciSparcs Palmitoylethanolamide (PEA) and Clearminds Methoxy-2-aminoindane (MEAI). The collaboration aims to develop ground-breaking treatments for global health challenges. Previous pre-clinical studies have shown promising results, including weight loss, improved fat utilization, and normalization of insulin levels. The partnership represents SciSparcs commitment to delivering transformative therapies for central nervous system disorders. The article does not mention any specific customers, acquisition or investment amounts, layoffs, or management changes. The event described in the article is dated June 16, 2023.

growth-positive

SciSparc Ltd has entered into a license and distribution agreement with its subsidiary, SciSparc Nutraceuticals Inc., granting the subsidiary an exclusive license to sell and market CannAmide™ on the Amazon.com marketplace in Canada. CannAmide™ is an oral formulation for the reduction of chronic pain and inflammation. The agreement is for a term of 12 months and allows for termination with 30-days notice. SciSparc Nutraceuticals plans to expand its reach by marketing its brands products in additional global markets and broadening its product offerings.

growth-positive

Jeffs Brands Ltd announced that SciSparc Nutraceuticals has entered into an exclusive license and distribution agreement to sell and market CannAmide on the Amazon.com marketplace in Canada. CannAmide is an oral formulation for the reduction of chronic pain and inflammation. SciSparc Nutraceuticals plans to expand its reach and broaden its product offering. The License Agreement is for a term of 12 months and may be terminated with 30-days notice.

growth-positive

SciSparc Ltd announced positive topline results from its Phase IIa trial for SCI-110, a therapy for Alzheimers disease and agitation. The trial demonstrated a high safety profile and significant improvement in agitation symptoms in elderly patients with Alzheimers disease. The trial medication was well-tolerated with no negative responses observed. The results support SciSparcs efforts to develop innovative treatments for central nervous system disorders. The trial was conducted at the Sophie & Abraham Stuchynski Israeli Alzheimer’s Medical Center and led by Dr. Alexander Kaplan. SciSparc is a specialty clinical-stage pharmaceutical company focused on cannabinoid-based therapies.

growth-positive

SciSparc Ltd. has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, as part of its corporate restructuring plan to unlock value for shareholders. Mr. Baranes will be responsible for structuring business strategies and identifying new business opportunities. The company aims to explore new opportunities, activities, and investments in various sectors. SciSparc is a specialty clinical-stage pharmaceutical company focused on developing therapies for disorders of the central nervous system, with a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The appointment of Mr. Baranes is expected to contribute to the companys growth and expansion.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, has announced the completion of treatment for the last patient enrolled in its Phase IIa trial of SCI-110 for Alzheimer’s Disease and agitation. The company previously announced positive interim results from the trial, which met its primary endpoints of safety. The trial also met its secondary endpoint of change from baseline to end of treatment in agitation. The company is expecting to receive the final trial results in the upcoming weeks.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has announced a new provisional patent application as part of its ongoing collaboration with Clearmind Medicine Inc. The patent application is for a novel psychedelic-based combination of Clearminds MEAI and SciSparcs Cannamide for the treatment of depression. This is the latest in a series of patent applications filed by Clearmind for combinations of its MEAI compound with SciSparc’s PEA for the treatment of various disorders.

growth-positive

SciSparc Ltd, a clinical-stage pharmaceutical company, has signed an agreement with Tikun Olam Cannbit Pharmaceuticals Ltd., a leading manufacturer and distributor of cannabis-based products in Israel. The agreement involves the supply of CBD-rich oil from Cannbit strains, which will be used as part of SciSparcs proprietary SCI-210 treatment. This treatment will be used in a clinical trial on children with autism spectrum disorder (ASD). The trial has been approved by the Israeli Ministry of Health and the Ethics Committee of the Soroka University Medical Center.

growth-positive

SciSparc Ltd announced that its joint venture MitoCareX Bio has achieved its first milestone by establishing a cloud-based computing infrastructure. As a result, SciSparc will invest an additional $400,000 in MitoCareX Bio and increase its share ownership. MitoCareX Bio focuses on the discovery and development of potential drugs for cancer, rare diseases, and other life-threatening conditions. The company believes that regulating the function of mitochondrial carriers could treat various life-threatening conditions. MitoCareX Bio is currently performing virtual screening activities and developing its drug discovery platform to enable machine learning capabilities. SciSparc is a specialty clinical-stage pharmaceutical company focused on cannabinoid pharmaceuticals.

growth-positive

SciSparc Ltd, a specialty clinical-stage pharmaceutical company, announced its ongoing collaboration with Clearmind Medicine Inc. in the development of novel psychedelic-based combinations. Clearmind has filed three provisional patent applications with the USPTO for proprietary combinations of LSD, psilocybin, and DMT with SciSparcs Palmitoylethanolamide (PEA). Three other patent applications have been filed for the combination of SciSparcs PEA with Clearminds MEAI compound for the treatment of alcohol use disorder, cocaine addiction, and obesity. The collaboration aims to maximize the therapeutic effect of the products and provide additional solutions for mental health problems. SciSparc focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics.

growth-positive

SciSparc Ltd. has received approval from the Soroka University Medical Center to conduct a clinical study for its SCI-210 treatment in patients with autism spectrum disorder (ASD). The study aims to evaluate the safety and efficacy of SCI-210, a combination of cannabidiol (CBD) and CannAmide™, compared to CBD monotherapy. The trial will involve 60 children with ASD and will assess the impact of SCI-210 on various measures of behavior and therapeutic dose. ASD is a condition that affects social interaction and communication. SciSparc is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders.

growth-positive

SciSparc Ltd. announced positive pre-clinical results in ongoing research studies of treatment for cocaine addiction using MEAI, a drug candidate from Clearmind Medicine Inc. The studies were conducted in collaboration between the two companies, and a patent application for treating cocaine addiction with Clearminds MEAI and SciSparcs CannAmide was submitted. The research showed that MEAI may be effective in reducing craving for cocaine without interrupting the natural reward process. SciSparc is a specialty clinical-stage pharmaceutical company focused on developing therapies for disorders of the central nervous system. Clearmind is a psychedelic pharmaceutical biotech company focused on developing psychedelic-derived therapeutics.

growth-positive

SciSparc Ltd. has entered into a non-binding letter of intent for the sale of a 50% interest in its subsidiary, SciSparc Nutraceuticals Inc., to Jeffs Brands Ltd. The sale is subject to negotiation and the execution of a definitive agreement. Additionally, the two companies have entered into a non-binding letter of intent to establish a joint venture for the development and online marketing of a new food supplements product line. SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on the development of therapies for disorders of the central nervous system. SciSparc Nutraceuticals Inc. owns the Wellution brand, which sells hemp-based products on Amazon.

growth-positive

SciSparc Ltd announced positive interim results from its Phase IIa trial of SCI-110 in patients with Alzheimer’s Disease and agitation. The trial met its primary endpoints of safety and showed amelioration in agitation with no need for rescue medication. The study medication was well tolerated with no negative response observed. SCI-110 is a combination of Dronabinol and CannAmide™, and it aims to provide a potential treatment option for Alzheimers patients with agitation. The company is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.

growth-positive

SciSparc Ltd announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. The results indicate a significant decrease in cocaine craving in a sub-group that received the treatment. The collaboration between SciSparc and Clearmind aims to develop a targeted treatment for cocaine addiction. The pre-clinical trial was led by Professor Gal Yadid and his team from Bar Ilan University. SciSparc is a specialty clinical-stage pharmaceutical company focused on the development of therapies for disorders of the central nervous system. Clearmind is a biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics.

growth-positive

SciSparc Ltd. has announced the appointment of Prof. Ciro Leonardo Pierri as a special advisor for MitoCareX Bio Ltd., their joint venture for the discovery and development of potential drugs for cancers, infectious diseases, and other life-threatening conditions. The JV focuses on investigating mitochondrial carriers and their role in transporting necessary metabolites for cell functioning. The company believes that regulating the function of mitochondrial carriers could potentially treat various infectious diseases and cancers. The appointment of Prof. Pierri brings expertise in biochemistry, structural biology, molecular modeling, and cell physiology to the JV. SciSparc is a specialty clinical-stage pharmaceutical company focused on cannabinoid pharmaceuticals and is currently engaged in drug development programs for various conditions.

growth-positive

SciSparc Ltd. announced positive results from a pre-clinical trial in collaboration with Clearmind Medicine Inc. The trial showed a significant dose-dependent effect for the MEAI treatment in reducing alcohol consumption in animals. The addition of CannAmide™ treatment further enhanced the effect at a lower sub-effective MEAI dose. The company plans to explore opportunities in the psychedelics market while continuing its cannabinoid-based clinical programs.

growth-positive

SciSparc Ltd. has announced the appointment of Mr. Oz Adler as the Chief Executive Officer, Mr. Itschak Shrem as the President, and Mr. Amitay Weiss as the chairman of the Board of Directors. Mr. Adler will continue to serve as the Chief Financial Officer until a suitable replacement is recruited. The company focuses on the development of therapies for central nervous system disorders, particularly cannabinoid pharmaceuticals. They are currently engaged in drug development programs for various conditions. The appointment of new executives indicates a positive growth direction for the company.

growth-positive

SciSparc Ltd. has entered into an agreement with two clinical sites to further its Phase IIb clinical study for SCI-110, a drug candidate for Tourette syndrome. The clinical trial will be conducted at Hannover Medical School in Germany and Tel-Aviv Sourasky Medical School in Israel. The company is partnering with renowned experts in cannabinoid-based therapeutics and movement disorders. The trial aims to evaluate the efficacy, safety, and tolerability of SCI-110 compared to placebo in treating adults with Tourette syndrome. Tourette syndrome affects approximately 1% of the worlds population, and there is currently no effective treatment. SCI-110 combines an FDA-approved synthetic form of THC with an endocannabinoid to increase efficacy and decrease side effects. SciSparc is focused on developing cannabinoid pharmaceuticals for various conditions.

growth-positive

SciSparc Ltd. has announced the recruitment of the first patient for its Phase IIa clinical trial evaluating the safety and efficacy of SCI-110 in patients with Alzheimers disease and agitation. The trial will be conducted at the Israeli Medical Center for Alzheimers. SCI-110 is a proprietary combination of Dronabinol and Palmitoylethanolamide. Alzheimers disease is a neurodegenerative disease that impairs cognitive functions and causes behavioral disturbances. The current pharmacological treatment for agitation in Alzheimers disease has limited benefits and often involves off-label drugs. SciSparc aims to provide an efficient treatment option for patients and their families.

Growth-Positive

SciSparc Ltd., a clinical-stage pharmaceutical company, has been granted a new patent by the U.S. Patent and Trademark Office. The patent, U.S. Patent No. 11,207,290, pertains to pharmaceutical compositions comprising cannabinoids and N-acylethanolamines. This is the fourth U.S. patent granted to SciSparc, which also recently received the same patent in Australia and Japan. The patent strengthens the companys intellectual property portfolio and protects its core technologies in key global markets.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, provided updates on its activities in 2021. The company reached important milestones, including the uplisting of its ordinary shares to the Nasdaq Capital Market. In 2021, SciSparc raised over $8 million in a private placement. The company also received patents from the Australian and Japanese Patent Offices for its proprietary compounds and methods. SciSparc provided updates on its pipeline status, including preparations for a Phase IIb clinical trial in Tourette Syndrome and a Phase IIa trial in Alzheimers disease and Agitation. The company also announced agreements and collaborations with medical centers and research organizations. SciSparc plans to expand its partners network, strengthen its professional team, and increase exposure to investors in North America.

growth-positive

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, announced that its ordinary shares will start trading on The Nasdaq Capital Market. The company focuses on the development of therapies for disorders of the central nervous system, particularly based on cannabinoid pharmaceuticals. They are currently engaged in drug development programs for various conditions such as Tourette syndrome, obstructive sleep apnea, Alzheimers disease, pain, autism spectrum disorder, and epilepsy. The announcement signifies a growth-positive impact on the company as it gains access to a larger market and increased visibility. The article also mentions forward-looking statements and the potential risks and uncertainties associated with them.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, has announced that its ordinary shares have been approved for listing on The Nasdaq Capital Market. The trading of the companys shares on Nasdaq is expected to begin on December 22, 2021. This uplisting to Nasdaq reflects the improvements made by the company, including a growing patent portfolio, advancements in clinical studies, and notable additions to the leadership team. The company believes that trading on Nasdaq will increase its visibility in the market and provide broader access to individual and institutional investors, enhancing its ability to develop therapeutics for central nervous system disorders.

growth-positive

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, announced the publication of a manuscript detailing the uses of its drug candidate SCI-110 for Tourette Syndrome. The manuscript describes the positive results of a phase IIa clinical trial conducted at Yale University, which showed a significant improvement in tic symptoms with SCI-110 treatment. The study also highlighted the collaboration between SciSparc and Yale University as an example of beneficial partnership between industry and academia. Based on the study results, SciSparc plans to initiate a randomized, double-blind, placebo-controlled study to further evaluate the safety and efficacy of SCI-110 in treating adults with Tourette Syndrome.

growth-positive

SciSparc Ltd., a specialty pharmaceutical company focusing on cannabinoid-based treatments, has completed its rebranding process and announced the development of proprietary compounds for CNS disorders. The company has several drug candidates in clinical trials and pre-clinical studies. They recently provided an update on their Phase IIb clinical study in Tourette Syndrome and received approval to commence a Phase IIa Clinical Trial in patients with Alzheimers Disease and Agitation. The rebranding and new website reflect SciSparcs vision and dedication to cannabinoid-based treatments. The companys focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.

growth-positive

SciSparc Ltd., a specialty pharmaceutical company, announced positive top-line results for its proprietary compound, SCI-160, in a pre-clinical trial on neuropathic and post-operative pain. The trial showed that SCI-160 significantly alleviates pain and has analgesic effects. The company aims to develop SCI-160 as a non-opioid option for pain treatment. The global postoperative pain management market is expected to reach $45 billion by 2026. SciSparc is focused on creating and enhancing a portfolio of cannabinoid-based pharmaceuticals. The company is also developing other drug programs for Tourette syndrome, obstructive sleep apnea, autism spectrum disorder, and epilepsy.

growth-positive

SciSparc Ltd. has announced updates regarding its Phase IIb clinical study in Tourette Syndrome using the proprietary cannabinoid-based treatment- SCI-110. The company has begun preparation for the study and engaged with a contract research organization (CRO) for support. SciSparc has also established its supply chain infrastructure for manufacturing and delivering the SCI-110 drug. The company is in contact with two potential clinical sites for hosting the study. The study aims to evaluate the efficacy, safety, and tolerability of SCI-110 in a randomized, double-blind, placebo-controlled, cross-over study. The primary objectives are to assess changes in YGTSS-R-TTS and the frequency of Serious Adverse Events (SAEs).

growth-positive

SciSparc Ltd. has received approval to commence a Phase IIa Clinical Trial of SCI-110 in patients with Alzheimers disease and agitation. The trial aims to demonstrate the safety and efficacy of SCI-110 in ameliorating agitation and other behavioral disturbances in patients with Alzheimers disease. The current medical treatment for agitation associated with Alzheimers is off-label use of antipsychotic drugs, which provide only marginal improvement with undesirable side effects. SCI-110, a combination of Dronabinol and CannAmide, is believed to be a safe and effective treatment for agitation in Alzheimers disease. Alzheimers disease is an irreversible neurodegenerative disease that causes cognitive impairment and neuropsychiatric symptoms. The pharmacological treatment of agitation in Alzheimers is an unmet need.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company specializing in cannabinoid-based treatments, has announced its participation and support for the 31st Annual International Cannabinoid Research Society Symposium. The company will sponsor an event celebrating the work of cannabinoid pioneer, Prof. Raphael Mechoulam. SciSparcs technology platforms are based on the entourage effect phenomenon, first discovered by Prof. Mechoulam. The company is currently developing various combination drug candidates and is also working on SCI-160, a novel pharmaceutical preparation containing a CB2 receptor agonist for the treatment of pain.

growth-positive

SciSparc Ltd. has entered an agreement with The Sheba Fund for Health Services and Research to conduct a pre-clinical study for its SCI-210 drug development program. The study aims to evaluate the potential advantage of SCI-210, a combination of non-psychoactive cannabinoid cannabidiol (CBD) and palmitoylethanolamide (PEA), for the treatment of Status Epilepticus (SE). The company hopes to demonstrate the efficacy of SCI-210 over CBD alone in treating SE and its neurological cognitive sequelae. The study will compare the effect of SCI-210 to CBD single treatment in an animal model of SE. The company believes that SCI-210 has the potential to reduce adverse effects associated with high-dose CBD treatments. The agreement with The Sheba Fund for Health Services and Research indicates a positive growth impact for SciSparc Ltd.

growth-positive

SciSparc Ltd. has been awarded two patents from the Australian Patent Office and one from the Japanese Patent Office for its proprietary compounds and methods underlying the companys core technologies. The patents strengthen the companys IP portfolio and competitive advantage in the emerging psycho-pharma market. SciSparc is a specialty clinical-stage pharmaceutical company focused on the development of therapies for disorders of the central nervous system. The company is currently engaged in drug development programs based on THC and/or non-psychoactive cannabidiol (CBD) for various conditions. The patents establish claims that safeguard the core technologies at the heart of the companys product pipeline.

growth-positive

SciSparc Ltd. has agreed to sell 1,152,628 Units to certain institutional and accredited investors in a private placement. The offering price is $7.07 per Unit. Each Unit consists of 1 American Depositary Share (ADS), 1 Series A Warrant, and ½ Series B Warrant. The anticipated gross proceeds from the offering will be approximately $8.15 million. The closing of the offering is expected to take place on or about March 4, 2021.

growth-positive

SciSparc Ltd., a clinical-stage pharmaceutical company, has announced a partnership with The Israeli Medical Center for Alzheimers to conduct a phase IIa clinical trial. The trial will evaluate the safety, tolerability, and efficacy of SCI-110, a proprietary cannabinoid-based treatment for patients with Alzheimers disease and agitation. The study will begin immediately after receiving the necessary approvals from the Institutional Review Boards and the Israeli Ministry of Health. The primary objective of the study is to assess the safety of SCI-110, while the secondary objective is to determine the compounds ability to alleviate agitation and other behavioral disturbances in Alzheimers patients.

Neutral

Clinical-stage pharmaceutical company SciSparc Ltd. has announced a change in its corporate name from Therapix Biosciences Ltd. The name change has been approved by the Israeli Registrar of Companies and is currently undergoing additional regulatory processes in the U.S., including obtaining a new ticker symbol and CUSIP number. The company, which focuses on the development of cannabinoid-based treatments, has stated that the name change will not affect the number of outstanding ordinary shares and ADSs.

growth-positive

Therapix Biosciences has announced the pricing of an offering for the issuance of units consisting of American Depositary Shares (ADS) and warrants. The offering is expected to result in gross proceeds of approximately $4,200,000. The company plans to use the net proceeds for partial repayment of a deposit, repayment of amounts drawn under a credit agreement, and for working capital and pursuing strategic opportunities. The closing of the sale of the units is expected to take place on November 23, 2020.

Growth-Positive

Therapix Ltd., a clinical-stage pharmaceutical company specializing in cannabinoid-based treatments, has announced a change in its board of directors. The new six-member board will include Itschak Shrem, Amitay Weiss, Moshe Revach, Lior Amit, Lior Vider, and Liat Sidi. Itschak Shrem will serve as the Chairman of the new board, and Amitay Weiss will assume the position of Chief Executive Officer of the Company. The company is confident that the new leadership will help maximize its potential and deliver a deserving return to its shareholders.

growth-negative

Therapix Biosciences Ltd., a specialty pharmaceutical company focusing on cannabinoid-based treatments, announced that its American Depositary Shares (ADSs) will now trade under the OTC Pink ticker symbol TRPXY. The company also reported the removal of a temporary injunction against the company by an Israeli court. The injunction had prohibited the company from making changes in its share capital or adopting resolutions outside the ordinary course of business. The court ruling stated that the previously announced Annual and Special General Meeting of Shareholders will be held on July 28, 2020, with a record date of July 7, 2020. The companys ADSs were suspended from trading on the Nasdaq Stock Market as of July 2, 2020.

growth-negative

Therapix Biosciences Ltd. has received a Notice of Delisting from the Nasdaq Hearings Panel, which will result in the delisting of the companys American Depositary Shares (ADSs) from The Nasdaq Capital Market. The suspension of trading in the ADSs will be effective on July 2, 2020. Additionally, the company has been granted a temporary injunction by an Israeli court, prohibiting it from making any changes in its share capital or adopting any resolution until a hearing scheduled for July 8, 2020. As a result, the closing of the companys previously announced $2.6 million private placement will not take place on July 1, 2020.

growth-positive

Therapix Biosciences has entered into definitive agreements with investors for a private placement of 5.2 million American Depositary Shares (ADSs) at a purchase price of $0.50 per ADS. The company will also issue warrants to purchase up to 2.6 million ADSs. The private placement is expected to result in gross proceeds of $2.6 million, which will be used for general corporate purposes. The closing of the sale of the securities is expected to take place on or about July 1, 2020.

growth-positive

Therapix Biosciences has closed a joint venture transaction for collaboration in the development of pharmaceuticals for a sleep-related indication. The company has also appointed Mr. Arie Webber to its Board of Directors. As part of the joint venture, Therapix transferred its THX-110 sleep technology to Evero. In addition, Therapix issued a warrant to Capital Point to purchase $340,000 of American Depositary Shares. The joint venture closed on May 18, 2020. The company is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.

growth-positive

Therapix Biosciences has announced the appointment of Gilad Bar-Lev as CEO, effective May 6, 2020. Bar-Lev will replace Dr. Ascher Shmulewitz, who will continue to serve as Chairman of the Board. Bar-Lev is an experienced investor with expertise in publicly traded securities, leveraged buyouts, and venture capital. The company expects Bar-Levs leadership to bring value to all stakeholders and strengthen Therapixs ability to succeed. Therapix Biosciences is a specialty clinical-stage pharmaceutical company focused on the development of cannabinoid-based treatments. They are currently engaged in drug development programs for various conditions. The appointment of Bar-Lev as CEO is seen as a positive growth move for the company.

growth-negative

Therapix Biosciences has received an extension until April 1, 2020, to regain compliance with the minimum stockholders equity requirement for continued listing on Nasdaq. The company is a specialty clinical-stage pharmaceutical company focused on the development of cannabinoid-based treatments. They are currently engaged in drug development programs for various conditions. The announcement contains forward-looking statements and highlights the risks and uncertainties the company faces. Therapix Biosciences is actively working to regain compliance and sustain its listing on Nasdaq.

growth-positive

Therapix Biosciences has entered into definitive agreements with several investors for a registered direct offering of 1,000,000 American depositary shares (ADSs) at a purchase price of $1.25 per ADS. The offering is expected to result in gross proceeds of $1,250,000, which will be used for general corporate purposes. The closing of the sale is scheduled for December 6, 2019. Therapix Biosciences is a specialty clinical-stage pharmaceutical company focused on the development of cannabinoid-based treatments.

growth-positive

Therapix Biosciences Ltd., a clinical-stage pharmaceutical company, announced the progression of its RESPECTRUM product candidate into clinical stage. The company plans to initiate a study to evaluate the efficacy, safety and tolerability of RESPECTRUM in treating patients with Autism Spectrum Disorder (ASD). The trial objective is to assess the efficacy and safety of RESPECTRUM versus cannabidiol (CBD)-rich oil by ASD severity measurements. The study will be conducted under the leadership of Dr. Orit Stolar, a Pediatric Neurologist at Shamir Medical Center in Israel.

growth-negative

Therapix Biosciences has received a written Notice of Delisting from Nasdaq due to non-compliance with the minimum stockholders equity requirement. The company plans to appeal the decision and request a hearing before a Nasdaq Hearings Panel. The delisting of the companys securities has been temporarily stayed pending the Panels decision. Therapix Biosciences previously submitted a plan to regain compliance, but it did not meet the requirements due to abandoning a proposed merger. If the appeal is not successful, the companys securities will be removed from listing and registration on Nasdaq. Therapix Biosciences is a specialty clinical-stage pharmaceutical company focused on the development of cannabinoid-based treatments.

growth-positive

Therapix Biosciences has signed a memorandum of understanding with Heavenly Rx Ltd for a reverse merger. The transaction is subject to a definitive agreement and regulatory approvals. Therapix will issue up to 20% of its outstanding ADSs to buy an interest in Heavenly Rx. This follows Therapixs decision to end merger talks with Destiny Biosciences. Antares has entered an agreement with Idorsia Pharma to develop a drug-device product. Crispr and Vertex have announced positive results for their mid-stage gene editing therapy. Karuna Therapeutics has commenced an underwritten public offering. Ascendis Pharma has reported its Q3 earnings. Pieris Pharmaceuticals, Myovant Sciences, and Heat Biologics are scheduled to present clinical trial data. Affimed and Medtronic are scheduled to release their earnings.

growth-positive

Therapix Biosciences has entered into a memorandum of understanding with Heavenly Rx to pursue a business combination. The parties will negotiate a definitive agreement for a reverse takeover of Therapix by Heavenly Rx. Therapix will issue up to 20% of its outstanding American Depositary Shares to acquire an interest in Heavenly Rx. The share exchange is expected to close within 30 days. If the business combination is consummated, Therapix plans to spin out its pharmaceutical research and development assets to shareholders. Therapix also plans to pursue financing in support of the proposed business combination. Heavenly Rx is a CBD wellness company focused on acquiring and scaling companies in the hemp CBD market. The proposed business combination is expected to position Heavenly Rx as a public company.

growth-negative

Therapix Biosciences and Destiny Biosciences Global Corp. have decided to discontinue negotiations on a proposed merger. Therapix is considering other options for a merger and exploring strategic offers. The company is focused on the development of cannabinoid-based treatments, including a CBD drug candidate for epilepsy and inflammatory conditions.

growth-positive

Therapix Biosciences announced positive results in its pre-clinical study evaluating THX-210, a cannabinoid-based treatment for epilepsy and inflammatory conditions. The study showed that THX-210, which contains CBD and PEA, demonstrated superior efficacy compared to CBD alone. The company sees potential applications for THX-210 and believes it could make a meaningful difference for patients.

growth-negative

Therapix Biosciences has been granted an extension by the Nasdaq Stock Market until November 18, 2019, to regain compliance with listing rules. The company previously received a letter notifying them that their stockholders equity was below the minimum required for continued listing. Therapix submitted a plan to regain compliance and must complete a stockholders equity raising transaction or other event by the deadline. If they do not satisfy the terms, their securities may be subject to delisting proceedings. Therapix announced a proposed merger with Destiny Biosciences Global Corp, which they believe will satisfy the minimum stockholders equity requirement. The merger will focus on Therapixs proprietary IP and Destinys genomics-based breeding techniques and development capabilities.

growth-positive

Therapix Biosciences has received a product license from Health Canada for its Palmitoylethanolamide (PEA) oral tablet CannAmide. The license allows the company to offer non-opiate pain management products for chronic pain relief. CannAmide is a cannabimimetic compound that regulates endocannabinoid levels and has a high safety profile. The approval of CannAmide is an important milestone for Therapix, as it is the companys first product approval. Additionally, Therapix has signed a letter of intent for a proposed merger with Destiny Bioscience Global Corp, which will focus on combining Therapixs proprietary IP and technology with Destinys genomics-based breeding techniques and development capabilities.

growth-positive

Therapix Biosciences Ltd. has signed a letter of intent for a proposed merger with Destiny Biosciences Global Corp. The merged company will focus on Therapixs technology and assets pertaining to clinical-stage pharmaceutical applications of cannabis, and will include Destinys genomics-based cannabis breeding techniques and development capabilities. The companies expect a definitive agreement of the merger to be signed during the third quarter of 2019. Upon closing, current Therapix equity holders are expected to own approximately 32% of the combined company.

growth-positive

Therapix Biosciences announced interim results from its Phase IIa clinical study, suggesting that THX-110 positively affects symptoms in adult subjects with obstructive sleep apnea. The study is being conducted at Assuta Medical Center in Israel. The interim report showed significant improvement in study parameters for four out of seven patients who completed the study. The study medication was well tolerated, with only two patients experiencing negative results. Therapix plans to initiate a randomized, double-blind, placebo-controlled study to further evaluate the safety and efficacy of THX-110. The topline results are anticipated in the second half of 2019. The company aims to provide a pharmacological treatment for obstructive sleep apnea, which currently relies on noninvasive ventilation devices and oral appliances.

growth-positive

Therapix Biosciences Ltd., an Israel-based cannabis company, has signed agreements with unidentified investors to raise $2.25 million in a registered direct offering. The company develops cannabis-based drugs for neurological conditions, pain management, and infectious diseases. In December, a deal to be acquired by Canadian FSD Pharma for $48 million worth of FSD stock was scrapped. The private placement, expected to close on April 1, will be used for general corporate purposes, product development, and debt repayment.

growth-positive

Therapix Biosciences has appointed Ambassador Ron Prosor as a global growth strategy and international business development advisor. Ambassador Prosor, a seasoned Diplomat for the Israeli Ministry of Foreign Affairs and Israels former Permanent Representative to the United Nations, will support Therapix in developing and executing its global growth strategy. This partnership aims to position Therapix as a global leader in cannabinoid platform technologies. The company believes that combining its ongoing operations with Ambassador Prosors business community connections will be beneficial for achieving its goals. Ambassador Prosor expressed excitement about being part of Therapixs technology development and believes that the companys products will make a difference in the lives of people in need of cannabis therapeutics.

growth-negative

FSD Pharma Inc.s acquisition of Therapix Biosciences Ltd. is still being negotiated, according to a filing by Therapix. FSD wishes to modify certain material terms of the transaction, and it is uncertain if negotiations will result in a definitive agreement. The stock of Therapix was down 6.42% by market close on Tuesday. FSD Pharma, a Canadian cannabis company, had agreed to buy Therapix for $48 million worth of FSD Pharma stock in October. The acquisition is seen as FSDs focus on the pharmaceutical aspects of cannabis.

growth-positive

Toronto-based FSD Pharma Inc. has announced plans to acquire Therapix Biosciences Ltd., an Israeli developer of cannabinoid-based drugs. The deal, which is expected to be finalised within 30 days, will see shareholders of Nasdaq-listed Therapix receive $48 million worth of FSD Pharma stock. Therapix, founded in 2004, develops drugs for the treatment of neurological conditions, pain management, and infectious diseases. The transaction will focus on Therapixs intellectual property, and related technology and assets pertaining to all clinical stage applications.

growth-negative

Therapix Biosciences has announced its decision to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange (TASE) while maintaining a continued listing of its American Depositary Shares (ADSs) on the Nasdaq Capital Market. The company aims to be subject to one set of listing regulations instead of two, allowing greater flexibility to execute its business and financing strategy and reducing costs of operations. The delisting is expected to become effective three months from the date of the request. Therapixs ADSs will continue to trade on the Nasdaq Capital Market and the company will remain subject to the rules and regulations of the U.S. Securities and Exchange Commission and Nasdaq Capital Market applicable to listed companies.

growth-positive

Therapix Biosciences has initiated non-clinical studies to evaluate the efficacy of its compound THX-150 in collaboration with the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center. The compound is believed to have synergistic effects in combating antibiotic drug resistance. The company aims to develop new antibacterials with a new mechanism of action. The collaboration will use genomic techniques to accelerate the elucidation of the compounds mechanism of action. The World Health Organization has classified antimicrobial resistance as a serious threat, and the development of new antibacterials is crucial. The Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center are mentioned as partners in the collaboration.

growth-negative

Therapix Biosciences announced that Dr. Elran Haber, the Chief Executive Officer, will step down from his position to pursue other professional opportunities. The companys Board of Directors is searching for a new U.S.-based CEO. Dr. Haber will continue to serve in his position during the search. The company expressed gratitude for Dr. Habers leadership and highlighted the progress made under his tenure, including a successful U.S. initial public offering and advancements in clinical development programs. Therapix Biosciences is a specialty clinical-stage pharmaceutical company focused on cannabinoid-based drugs. They are currently engaged in two drug development programs targeting Tourettes syndrome and mild cognitive impairments.

growth-positive

Therapix Biosciences, a company developing treatments for Alzheimers and Tourette syndrome, has raised $12 million in an offering on Nasdaq. The companys shares will be listed on Nasdaq under the ticker TRPX. Therapix is currently developing two drugs based on synthetic THC for Tourette syndrome and early cognitive impairment in Alzheimers. The company plans to undergo the registration process with the US Food and Drug Administration for these drugs. The offering proceeds are $10.3 million net, with an option for underwriters to buy further ADRs worth $1.8 million. The stock price has been volatile, with a 30% increase this year. Therapix is controlled by the Jesselson family, Haim Amir, and Dr. Ascher Shmulewitz.

growth-positive

Therapix Biosciences Ltd. has announced the pricing of its initial public offering (IPO) in the United States. The company plans to offer 2,000,000 American Depository Shares (ADSs) at a price of $6.00 per ADS. The gross proceeds from the offering are expected to be $12,000,000. The net proceeds will be used to advance the formulation and clinical development efforts for its two lead product candidates, as well as for working capital and other general corporate purposes. The ADSs are scheduled to begin trading on the NASDAQ Capital Market on March 22, 2017. Laidlaw & Company (UK) Ltd. is acting as the sole book running manager for the offering.

growth-positive

Therapix Biosciences has entered into a memorandum of understanding with a Swiss pharmaceutical development company to receive a worldwide and exclusive license for the formulation of sublingual administration of ultralow dosages of THC. The company aims to develop and market this formulation for the treatment of cognitive impairments. The final agreement is subject to the completion of an initial clinical trial and technology due diligence. Therapix Biosciences has also filed an application with the FDA for an orphan drug designation for a drug developed based on the entourage technology for treating Tourette syndrome. The company specializes in the development and commercialization of cannabinoid-based drugs.

growth-positive

Therapix Biosciences has filed an application with the U.S. Food and Drug Administration for an orphan drug designation for a drug developed based on the entourage technology to treat Tourette syndrome. The orphan drug designation would provide several incentives, including market exclusivity, tax benefits, and assistance in regulatory proceedings. The company is also preparing for clinical trials and has recently added internationally renowned experts to its scientific board and team of consultants. Therapix Biosciences specializes in the development and commercialization of cannabinoid-based drugs.

growth-positive

Therapix Bio has announced that its American Depository Receipts (ADRs) have been registered and approved for trading on OTCQB. The listing of the ADRs is expected to support increased exposure among investors in the U.S. and other major financial centers. Therapix is a specialty pharmaceutical company focused on synthetic cannabinoid-based therapies and is executing its strategy through acquisitions of cannabinoid-focused companies and technologies. The company recently signed a definitive investment agreement with Lara Pharm Ltd., a private company engaged in the field of medical cannabis. Therapixs portfolio includes a unique synthetic formulation of THC administered through an inhaler and an orally administered anti-CD3 antibody for the treatment of various inflammatory diseases.